Merck announces Phase 3 KEYNOTE-826 trial of pembrolizumab plus platinum-based chemotherapy with or without bevacizumab met dual primary endpoints in patients with metastatic cervical cancer
RCT (n=617) suggest treatment significantly improved overall survival & progression-free survival compared to platinum-based chemotherapy with or without bevacizumab alone as first-line treatment, for persistent, recurrent or metastatic cervical cancer regardless of PD-L1 Status.
Source:
Biospace Inc.